Objective: To identify neuropsychological predictors of treatment response to cognitive-behavioral therapy (CBT) and fluoxetine in treatment-naïve adults with obsessive-compulsive disorder (OCD). Method: Thirty-eight adult outpatients with OCD underwent neuropsychological assessment, including tasks of intellectual function, executive functioning and visual and verbal memory, before randomization to a 12-week clinical trial of either CBT or fluoxetine. Neuropsychological measures were used to identify predictors of treatment response in OCD. Results: Neuropsychological measures that predicted a better treatment response to either CBT or fluoxetine were higher verbal IQ (Wechsler Abbreviated Scale of Intelligence) (p = 0.008); higher verbal memory on the California Verbal Learning Test (p = 0.710); shorter time to complete part D (Dots) (p b 0.001), longer time to complete part W (Words) (p = 0.025) and less errors on part C (Colors) (p b 0.001) in the Victoria Stroop Test (VST). Fewer perseverations on the California Verbal Learning Test, a measure of mental flexibility, predicted better response to CBT, but worse response to fluoxetine (p = 0.002). Conclusion: In general, OCD patients with better cognitive and executive abilities at baseline were more prone to respond to either CBT or fluoxetine. Our finding that neuropsychological measures of mental flexibility predicted response to treatment in opposite directions for CBT and fluoxetine suggests that OCD patients with different neuropsychological profiles may respond preferentially to one type of treatment versus the other. Further studies with larger samples of OCD patients are necessary to investigate the heuristic value of such findings in a clinical context.
Introduction
Obsessive-compulsive disorder (OCD) is a chronic mental illness associated with significant distress and impaired functioning (Koran, 2000; Leon et al., 1995) . Its lifetime prevalence is estimated to be 2-3% (Ruscio et al., 2010a (Ruscio et al., , 2010b Weissman et al., 1994) and accumulating evidence supports the efficacy of two treatment interventions: cognitive-behavioral therapy (CBT), which includes exposure and response prevention (Foa et al., 2005) and pharmacotherapy, primarily serotonin reuptake inhibitors (Fineberg and Gale, 2005) . Overall, up to 60% of patients receiving one of these treatments or a combination of the two will exhibit a clinically significant reduction in obsessivecompulsive symptoms (OCS), although residual symptoms are often the rule rather than the exception (Pallanti et al., 2002) .
Neuropsychological approaches have proven to be important tools in the investigation of cognitive functioning in OCD (Kuelz et al., 2004; Olley et al., 2007) . In previous studies, certain neuropsychological domains, specially related to executive functioning, such as planning, cognitive flexibility, response inhibition, decision making and attentional bias/vigilance, were found to be impaired in OCD patients (Bérdard et al., 2009; Bespalov et al., 2010; Bolton et al., 2000; Cavedini et al., 2002; Chamberlain et al., 2005; Menzies et al., 2008; Olley et al., 2007; Shin et al., 2010) although inconsistent results have been reported (Kuelz et al., 2004) . Possible reasons for disparities in some neuropsychological findings in OCD might be explained by methodological issues such as small and heterogeneous samples of OCD participants, matching criteria and comorbidities, and particularly previous exposure to medications (Kuelz et al., 2004; Simpson et al., 2006) .
There is also evidence that some neuropsychological deficits in OCD, such as those in nonverbal memory, set shifting, planning, organizational skills and problem-solving may improve with CBT and pharmacological treatments (Kuelz et al., 2006; Park et al., 2002) . There are also other findings showing that some neuropsychological impairments, such as inhibitory control and verbal fluency, remain present even after successful treatment (Kim et al., 2002; Thienemann and Koran, 1995) . Furthermore, impairments in executive function domains have been shown to be associated with treatment response to specific treatment modalities (Cavedini et al., 2002; Flessner et al., 2010; Fontenelle et al., 2001) . For example, poorer response to CBT has been associated to lower scores in tests of semantic verbal fluency and learning of visual association pairs (Cavedini et al., 2002) , whereas impaired set-shifting ability, measured by the Wisconsin Card Sorting Test (WCST), has been associated with better therapeutic response to fluoxetine (Fontenelle et al., 2001) . Moreover, poorer decision-making performance predicted poorer outcome to pharmacological treatment (Cavedini et al., 2002) . In youths with OCD, poorer performance on the Rey-Osterrieth Complex Figure Test predicted poorer response to treatment, particularly among those receiving CBT alone (Flessner et al., 2010) . On the other hand, some trials have found no association between pretreatment neuropsychological performance (visuospatial construction, visual memory, and set-shifting) and response to CBT (Bolton et al., 2000; Moritz et al., 2005) .
Notwithstanding the studies described above, neuropsychological investigations designed to examine predictors of treatment response in clinical trials comparing simultaneously the two main modalities of intervention are lacking in OCD. This is unfortunate, given evidence in literature suggesting distinct neurobiological mechanisms of action of CBT and pharmacotherapy in OCD (Hoexter et al., 2012) .
Therefore, to address these limitations, this study aimed to evaluate neuropsychological predictors of treatment response using a broad neuropsychological battery, focusing mainly on executive functions. The sample consisted of treatment-naïve adult OCD patients submitted to a 12-week randomized clinical trial of CBT and fluoxetine. The selection of a treatment-naïve population aims to exclude the potential confounding bias of previous treatments on neuropsychological domains (Bolton et al., 2000; Kang et al., 2003; Kim et al., 2002; Krishna et al., 2011) . We hypothesized that better neuropsychological performance in respect to executive function, i.e., inhibitory control; cognitive flexibility and planning would predict greater response to both treatment modalities (CBT or fluoxetine). However, given that CBT is assumed to rely on executive functions, specifically cognitive flexibility (Beck, 1995) , patients with better performance on mental flexibility and learning would be more likely to improve after CBT if compared to fluoxetine. Additionally, we explored whether sociodemographic and clinical variables could influence treatment response.
Methods
The present study is a part of a research protocol evaluating multiple neurobiological measures in treatment-naïve OCD patients (Hoexter et al., 2009) . Study subjects participated in a larger clinical trial designed to compare the effectiveness of group CBT versus fluoxetine (Belotto-Silva et al., 2012) (registration at http://clinicaltrials.gov -NCT00680602). A detailed description of the assessment instruments (training, and reliability) can be found in the literature (Miguel et al., 2008) . From 2006 to 2008, 369 subjects underwent clinical and psychiatric medical assessment in the OCD outpatient clinic at the Institute & Department of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil. From these, 50 treatment-naïve OCD patients fulfilling inclusion criteria accepted participation in this study.
The required written informed consent was approved by the Research Ethics Committee of the University of Sao Paulo and signed by all participants.
Inclusion and exclusion criteria
Inclusion criteria were: age between 18 and 65 years; DSM-IV diagnosis for OCD; score ≥ 16 on Y-BOCS; and, in the presence of other comorbid Axis I diagnoses, OCD as the primary and most severe diagnosis in terms of impairment. Patients were excluded if: they had prior exposure to any psychotropic medication or cognitive behavior therapy (at least 12 sessions); had a general medical condition (such as history of head injury with post-traumatic amnesia); or had severe mental illness other than OCD (i.e., psychotic disorder, active phase bipolar disorder, major depression with significant risk of suicide).
Clinical assessment
A broad range of clinical instruments was used, including the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) (First et al., 1995) , the Y-BOCS, the Dimensional Y-BOCS (DY-BOCS) , the Beck Depression Inventory (BDI) (Beck et al., 1961) and the Beck Anxiety Inventory (BAI) (Beck et al., 1988 ) (see Hoexter et al., 2009; Belotto-Silva et al., 2012 for more details).
Neuropsychological assessment
Prior to treatment initiation, patients underwent a neuropsychological evaluation. Testing averaged approximately three hours. The application of neuropsychological tests followed a set presentation order. Instruments that required attention and memory were administered early in the session when subjects were less susceptible to fatigue. The application of tests and scoring were performed by a trained neuropsychologist who was blinded to group assignment. Given that previous studies performed in OCD patients have emphasized impairments in specific neuropsychological domains involving executive functions (planning, cognitive flexibility, response inhibition, decision making and attentional bias/vigilance) (Cavedini et al., 2002; Kuelz et al., 2004; Menzies et al., 2008; Shin et al., 2010) , we selected the following tests:
The Wechsler Abbreviated Scale of Intelligence (WASI) was used to estimate full IQ (Wechsler, 1999) .
Attention
Digit Span (Forward and Backward) was used to assess auditory attention and short-term retention capacity (Wechsler, 1981) .
Trail Making Test (TMT) was used to assess complex visual scanning, visual search speed, visual attention, mental flexibility (Part B), and inhibitory control (Wechsler, 1997a (Wechsler, , 1997b .
Executive function
Object Alternation Task (OAT) (Freedman, 1990 ) was used as a measure of cognitive flexibility.
Hayling and Brixton Test (Burgess and Shallice, 1997) evaluated initiation speed as well as response suppression, while the Brixton Spatial Anticipation (Burgess and Shallice, 1997) test was used as a rule attainment task.
The Wisconsin Card Sorting Test (WCST) (Heaton, 1981 ) assessed abstract behavior, set shifting, response inhibition and mental flexibility.
Victoria Stroop Test (VST) (Regard, 1981) was used to determine selective attention, mental flexibility and inhibitory control.
The Iowa Gambling Task (IGT) (Bechara et al., 1994 ) evaluated decision making.
Memory and learning
Logical Memory (Wechsler, 1997a (Wechsler, , 1997b ) assessed contextualized short-and long-term memory.
The California Verbal Learning Test (CVLT-II) (Delis et al., 2000) measured verbal memory and learning.
The Brief Visual Motor Test -Revised (BVMT-R) (Benedict, 1997) was used to measure visual memory and learning.
The Rey-Osterrieth Complex Figure ( ROCF) (Osterrieth, 1944 ) assessed visual-spatial constructional ability and visual memory.
Language
The COWA (Spreen and Strauss, 1998 ) assessed verbal fluency under defined conditions.
Treatment allocation
After accepting to participate, patients were sequentially allocated to receive treatment between group CBT or fluoxetine. This procedure aimed to minimize possible differences between groups before treatment by adjusting for prognostic factors, such as initial Y-BOCS score, gender, and age (Fossaluza et al., 2009 ).
Treatment protocols
Patients allocated to CBT were divided into subgroups of 6-8 patients and attended weekly 2-hour therapy sessions for 12 weeks, with three additional follow-up sessions. The protocol emphasized exposure and response prevention exercises as well as cognitive techniques, such as correction of thoughts/beliefs and relapse prevention strategies. Patients allocated to pharmacological treatment received fluoxetine (up to 80 mg/day or maximum tolerated dosage) for 12 weeks, starting at 20 mg/day in the first week, with 20 mg weekly increases (Belotto-Silva et al., 2012).
Criteria for treatment response
The primary outcome measure for treatment response in this study was percent reduction in baseline Y-BOCS scores.
Treatment response was analyzed as a continuous variable, in terms of degrees of response, calculated as follows:
Statistical analyses
Statistical analysis was performed using the computer program R, version 2.9.0 and the Statistical Package for Social Sciences (SPSS) for Windows, version 14.0.P. Statistic indicators inferior to 0.05 were considered statistically significant.
The Mann-Whitney or the chi-square tests were used to evaluate demographic and clinical variables. Correlation between neuropsychological testing results and treatment response (defined as the reduction of initial Y-BOCS scores) was tested using Pearson's correlation coefficient.
Generalized linear models (Mccullagh and Nelder, 1989) were employed to determine the combined influence of neuropsychological parameters on treatment response. Only data from patients who completed the 12-week protocol was used. The following variables were included: treatment type (i.e., CBT or fluoxetine), sociodemographic variables (i.e., gender, age and years of formal education), clinical variables (i.e., Y-BOCS, Beck-A and Beck-D scores) and those neuropsychological variables which presented minimal correlation (p-valueb 0.15) with treatment response (i.e., CVLT-II perseverative responses, CVLT-II Total recall, IGT A+B, WCST learning to learning, Matrix Reasoning and Verbal IQ on the WASI, VST: part W-word, part C-colors, part C-colors errors, part D-dots, TMT B time and errors). We included first-order interactions between sociodemographic, clinical and neuropsychological variables and treatment type. The final variable and test protocol model was chosen based on the AIC (Akaike Information Criterion) and BIC (Bayesian Information Criterion).
In order to test the power of our statistical model, we executed a "power analysis" using the G*Power v. 3.1.3. Including 38 subjects and 10 explanatory variables, we obtained a 0.9999983 "adequateness" index to validate this model.
Results

Sample
Of the 50 OCD patients initially enrolled in the trial, 12 (24%) dropped out in a very early stage of the clinical trial (5 participants from the CBT and 7 from the fluoxetine group). Reasons for abandonment in the CBT group were fast initial reduction of symptoms (n=2), treatment allocation dissatisfaction (n=2), and failure to comply with sessions (n=1). Reasons for abandonment in the fluoxetine group included failure to comply with consultations (n=4), treatment allocation dissatisfaction (n=2) and intolerable side effects (n=1). Therefore, only data from the completers (CBT=18 and fluoxetine=20) was analyzed.
Demographic and clinical characteristics in treatment groups (CBT and fluoxetine)
At baseline, patients assigned to the two treatment groups (CBT and fluoxetine) were similar in terms of demographic (Table 1 ) and clinical characteristics ( Table 2) . As can be observed, there was no statistical significant difference between groups in the major sociodemographic and clinical variables.
Treatment outcome
The mean reduction in Y-BOCS score after treatment was 36% (36.0% for the CBT group and 36.1% for the fluoxetine group, p = 0.8). The effect size (Cohen's d) between initial and final YBOCS for CBT was 1.17, and for fluoxetine, 1.53, without significant statistical difference between treatments (p= 0.08).
Neuropsychological performance at baseline
Intelligence and neuropsychological measures were similar between treatment groups, with the exception of similarities (WASI), CVLT-II measures -total recall, short delay cued recall, long delay cued recall, recognition hits, semantic clustering and OAT, in which patients allocated to fluoxetine showed better performance (Table 3) .
Clinical predictors of treatment response
In our sample, age emerged as a predictor of treatment response to fluoxetine and had a small influence in predicting response to CBT. Elderly individuals responded better to fluoxetine, whereas, less extensively, younger individuals responded better to CBT (p b 0.001). In terms of the severity of OCS, higher initial Y-BOCS scores predicted a better response to both treatments (pb 0.001).
Neuropsychological predictors of treatment response
The neuropsychological domains that were predictive of response to treatment in this study were as follows (Table 4) :
Intelligence: a higher score on the verbal IQ section of the Wechsler Abbreviated Scale of Intelligence was found to be predictive of a better response to CBT and had a small influence on response to fluoxetine (p = 0.008). Verbal memory and learning: better performance on the total recall portion (Trials 1-5 correct) of the CVLT-II translated to a better response to fluoxetine and presents a slight influence to CBT response (p = 0.013). Mental flexibility: fewer perseverations (CVLT-II) predicted a better response to CBT (p = 0.002) but worse response to fluoxetine (p = 0.003). Abbreviations: DY-BOCS = Dimensional Yale-Brown Obsessive-Compulsive Scale. I -aggression, violence and natural disasters; DY-BOCS, II -sexual and religious; IIIsymmetry, ordering, arranging; IV -contamination and cleaning; V -hoarding; PTSD -post-traumatic stress disorder; ADHD -attention deficit hyperactivity disorder. Inhibitory control: a shorter time to completion of part D (Dots) of the Victoria Stroop Test (VST) was predictive of a better response to both treatments (p b 0.001). A longer time to completion of part W (Words) was predictive of a better response to both treatments (p = 0.025). In part C (Colors), OCD patients who committed few errors showed a better response to both treatments, a result much more pronounced for CBT (p b 0.001).
Hypothetical predictive model of treatment response
Considering that our generalized linear model was appropriate and had good treatment response predictive power, we hypothetically and illustratively explored the Y-BOCS expected response rate of a given patient, based on his/her demographic, clinical characteristics and neuropsychological performance. For instance, as can be seen in Table 5 , an OCD patient with age 39, initial YBOCS 25, and the following neuropsychological performance: 50 (raw score) on CVLT total recall, 114 (raw score) on verbal IQ, 20 s to complete the VST part D, 30 s to complete the VST part W, and 2 errors on VST part C, would present a 37% improvement in Y-BOCS scores if submitted to CBT and 12% if submitted to fluoxetine. On the other hand, another patient with the same age 39, initial YBOCS 25, and the following neuropsychological performance: 40 (raw score) on CVLT total recall, 111 (raw score) on verbal IQ, 15 seconds to complete the VST part D, 25 s to complete the VST part W, and 1 error on VST part C, would present a 18% improvement in Y-BOCS scores if submitted to CBT and 57% if submitted to fluoxetine.
Discussion
To our knowledge, this is the first study to investigate neuropsychological predictors of treatment response in a sample of adult treatment-naïve OCD patients submitted to CBT or fluoxetine in a randomized design. Both treatments were shown to be effective in reducing obsessive-compulsive symptoms. The advantage of including OCD patients never submitted to treatment is the exclusion of potentially confounding effects of previous interventions on neuropsychological measures.
Congruently with our initial hypothesis, higher baseline neuropsychological performance predicted better treatment response to both treatments, with the exception of mental flexibility, in which fewer perseverations predicted better response to CBT, but worse response to fluoxetine.
Sociodemographic and clinical predictors of treatment response
In our sample, older patients had a better treatment response to fluoxetine, whereas, less extensively, among those who were submitted to CBT, younger individuals responded better. In previous studies age has not been associated with treatment outcome in OCD (Ginsburg et al., 2008; Maher et al., 2010) . On the other hand, some studies have found that longer periods without being treated were predictive of worse response to pharmacological treatments for OCD (Ravizza et al., 1995) , suggesting that longer illness duration (which may be correlated to age) could be linked to the development of neurobiological abnormalities that make the disorder more resistant to pharmacological response.
Our findings, however, go in the opposite direction: older patients in this treatment naïve sample had a better treatment response to fluoxetine. We do not have a clear understanding for this discrepancy. We speculate that other clinical variables associated to treatment response may have played a role on this regard. Many clinical variables, beyond age and illness duration, are associated with poor response to treatment in OCD, such as more severe OCD symptoms, anxiety and depression (Ferrão et al., 2006; Mataix-Cols et al., 1999) , earlier onset of obsessive-compulsive symptoms (Fontenelle et al., 2003; Ravizza et al., 1995; Rosário-Campos et al., 2001 ) and a greater comorbidity profile (McDougle et al., 1990; Shavitt et al., 2006) . Interestingly, in an exploratory analysis, dividing our patients in the fluoxetine-group (n=20) according to the median age (30 years), subjects with age≤30 presented significantly higher scores on measures of depression (BDI) (mean±SD: 21.4±5.5), anxiety (BAI) (mean±SD: 21.8±8.1) and had an earlier onset of obsessive-compulsive symptoms (mean±SD: 8.5±1.7) compared to subjects with age>30 (BDI mean±SD: 12±6.4; BAI mean±SD 10.3±8.7: and age of onset of OCS mean±SD: 15.5±9.5) (p≤0.05). These subgroups did not differ in terms of obsessive-compulsive symptom severity (Y-BOCS scores mean±SD: 25.7±5.0 for patients with age≤30 and Y-BOCS scores mean±SD: 24.6±5.5 for patients with age>30). Therefore, in our study, older patients may have responded better to fluoxetine because they were less depressed and anxious and had a later onset of OCS, in spite of longer illness duration.
In addition, our findings suggested that younger patients submitted to CBT presented a better treatment response than older patients. Given that CBT is assumed to rely on cognitive skills known as executive functions (Beck, 1995) , one possible reason for this result may be the to CBT treatment while more perseveration predicted better response to fluoxetine. higher age-related decrements in executive function observed in older subjects (Gorenstein and Papp, 2007) . However, this interpretation should be taken cautiously. It should be acknowledged that in our statistical model, age exhibited a weak influence in predicting CBT response (Table 4) . Moreover, our OCD sample comprised patients with a maximum age of 65, precluding us to compare our findings to other studies that found cognitive rigidity in older subjects (Gorenstein and Papp, 2007) . Though the great majority of treatment response studies suggests that more severe OCD symptoms predict worse response to treatment (Ferrão et al., 2006; Mataix-Cols et al., 1999) , our findings have shown that more severe OCS were predictive of better treatment response to CBT and fluoxetine. It should be highlighted that previous treatment response studies included patients with OCD that had already been treated, whereas in our study patients were treatmentnaïve. Therefore, one might argue that the likelihood of first attempt treatment responses (measured by changes in Y-BOCS score percentages), is greater in patients with more severe OCS. However, limited literature investigating treatment response in treatment naïve patients restrains firmer speculations.
Neuropsychological predictors of treatment response
Verbal IQ, verbal memory and learning
The association of higher verbal IQ and better response to CBT may be a consequence of the fact that patients with greater verbal repertoire may better understand CBT techniques. Therefore, patients with superior verbal skills are better candidates for cognitive restructuration (Kuelz et al., 2006) . Our findings suggested that verbal IQ also predicted treatment response to fluoxetine in a much lesser extent. This supports the concept that IQ, in general, is a good predictive measure of treatment outcome (Buitelaar et al., 1995) . Likewise, the association between higher performance on verbal learning memory tasks (CVLT-II on Trials 1-5 correct) and better response to both treatments reinforce a general concept that patients with greater cognitive abilities (a brain with more functional reserve) are candidates to better respond to treatment (Spreen and Strauss, 1998) .
Executive functions
Fewer perseverations predicting a better response to CBT and worse fluoxetine response suggest that OCD patients with different mental flexibility profiles may preferentially respond to one type of treatment versus the other. In addition, our results corroborate previous studies showing that executive dysfunction is related to a worse prognosis in patients with OCD who are receiving CBT (Flessner et al., 2010) . Fewer perseverations are a marker of better mental flexibility (Cavedini et al., 2002; Kuelz et al., 2004) , which is certainly advantageous in the setting of learning alternative behaviors as demanded in CBT. Conversely, more perseverations have been reported to be associated with a better response to fluoxetine (Fontenelle et al., 2001) . There is evidence suggesting that altered serotonergic function, a neurotransmission system by which SRIs exert its action in the prefrontal cortex (El Mansari and Blier, 2006) , relates to deficits in mental flexibility in OCD patients (Hollander and Wong, 1996) . Therefore, our results suggest that more impaired mental flexibility should be better acknowledged as a tailoring variable for determining fluoxetine treatment response.
Regarding VST, better inhibitory control was predictive of better treatment response to both treatments. In previous studies, failure in this domain has been postulated as an endophenotype in OCD (Lennertz et al., 2012; Rajender et al., 2011) and has been associated with treatment response to antidepressants in anxiety disorders (Bespalov et al., 2010) . In the CBT context, having a more efficient inhibitory control may help individuals with OCD to inhibit maladaptive behaviors in order to generate newer adaptive responses. In addition, given that antidepressants modulate serotonergic neurotransmission in prefrontal regions (El Mansari and Blier, 2006) , subjects with a more preserved cognition, evidentiated by a better performance in inhibitory control, are also prone to respond to SRIs.
Limitations
This study must be interpreted in the light of some limitations. First, the small sample size and the heterogeneous nature of our participants with respect to their psychiatric comorbidities may have added variability to our findings. Thus, our results should be considered exploratory and our findings deserve independent replication before generalization. Second, unexpectedly, some baseline performance measures, such as similarities in the WASI and total recall in the CVLT-II, differed between groups, which may limit the interpretation of our data. However, it must be acknowledged that the perseveration scores did not differ between groups, reinforcing that this characteristic (cognitive rigidity) indeed shows an opposite effect on treatment response across the two groups.
Conclusion
Our study showed that better cognitive performance (i.e., intelligence, verbal memory/learning and inhibitory control) predicts better response to treatment regardless of treatment modality in OCD. On the other hand, given the opposite influence of mental flexibility in predicting treatment response to CBT and fluoxetine our results highlight that different neuropsychological performances may be involved in treatment response for each intervention. Therefore, depending on individual neuropsychological profile, treatment response to a given intervention may differ suggesting that particular treatment can be assigned according to specific neuropsychological features (e.g.: OCD patients with higher verbal IQ and less perseveration tend to respond better to CBT, whereas subjects with better inhibitory control, but more perseverations may respond better to fluoxetine). Patient 1  CBT  39  25  50  114  20  30  2  37%  Fluoxetine  39  25  50  114  20  30  2  12%  Patient 2  CBT  39  25  40  111  15  25  1  18%  Fluoxetine  39  25  40  111  15  25  1  57% 
